| Acute pulmonary oedema: clinical characteristics, prognostic factors, and in-hospital management. | |
| | |
MedLine Citation:
|
PMID: 20837636 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: Acute pulmonary oedema (APE) is the second, after acutely decompensated chronic heart failure (ADHF), most frequent form of acute heart failure (AHF). This subanalysis examines the clinical profile, prognostic factors, and management of APE patients (n = 1820, 36.7%) included in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). METHODS AND RESULTS: ALARM-HF included a total of 4953 patients hospitalized for AHF in Europe, Latin America, and Australia. The final diagnosis was made at discharge, and patients were classified according to European Society of Cardiology guidelines. Patients with APE had higher in-hospital mortality (7.4 vs. 6.0%, P = 0.057) compared with ADHF patients (n = 1911, 38.5%), and APE patients exhibited higher systolic blood pressures (P < 0.001) at admission and higher left ventricular ejection fraction (LVEF, P < 0.01) than those with ADHF. These patients also had a higher prevalence of diabetes (P < 0.01), arterial hypertension (P < 0.001), peripheral vascular disease (P < 0.001), and chronic renal disease (P < 0.05). They were also more likely to receive intravenous (i.v.) diuretics (P < 0.001), i.v. nitrates (P < 0.01), dopamine (P < 0.05), and non-invasive ventilation (P < 0.001). Low systolic blood pressure (P < 0.001), low LVEF (<0.05), serum creatinine ≥1.4 mg/dL (P < 0.001), history of cardiomyopathy (P < 0.05), and previous cardiovascular event (P < 0.001) were independently associated with increased in-hospital mortality in the APE population. CONCLUSION: APE differs in clinical profile, in-hospital management, and mortality compared with ADHF. Admission characteristics (systolic blood pressure and LVEF), renal function, and history may identify high-risk APE patients. |
| | |
Authors:
|
John T Parissis; Maria Nikolaou; Alexandre Mebazaa; Ignatios Ikonomidis; Juan Delgado; Fabio Vilas-Boas; Ioannis Paraskevaidis; Antony Mc Lean; Dimitrios Kremastinos; Ferenc Follath |
Related Documents
:
|
18216206 - Individual differences in stressor-evoked blood pressure reactivity vary with activatio... 11095166 - Epidemiology of hypertension in china and japan. 11433126 - Cardiovascular risk and therapeutic intervention for the early morning surge in blood p... 19012806 - Conference on "multidisciplinary approaches to nutritional problems". postgraduate symp... 16519016 - Pathophysiology of unilateral pulmonary aspergillosis in an experimental rat model. 6195456 - Effects of inotropic and chronotropic stimuli on acute myocardial ischemic injury. ii. ... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-09-13 |
Journal Detail:
|
Title: European journal of heart failure Volume: 12 ISSN: 1879-0844 ISO Abbreviation: Eur. J. Heart Fail. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-22 Completed Date: 2011-03-14 Revised Date: 2011-06-08 |
Medline Journal Info:
|
Nlm Unique ID: 100887595 Medline TA: Eur J Heart Fail Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 1193-202 Citation Subset: IM |
Affiliation:
|
Heart Failure Clinic and Second Cardiology Department, Attikon University Hospital, University of Athens, Athens, Greece. jparissis@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Comorbidity Creatinine / blood Female Heart Failure / epidemiology, etiology, physiopathology, therapy Hospital Mortality Humans Male Middle Aged Prognosis Pulmonary Edema / complications, epidemiology, physiopathology*, therapy ROC Curve Stroke Volume Ventricular Dysfunction, Left / epidemiology |
| Chemical | |
Reg. No./Substance:
|
60-27-5/Creatinine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction.
Next Document: Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a m...